Overview
- The stock, which set an intraday 52‑week low on Thursday, has plunged roughly 30–40% year to date and recorded its worst monthly drop in years as key technical support levels broke.
- Palantir reported very strong Q1 results with revenue up about 85% year over year, non‑GAAP EPS rising 154%, $2.4 billion of new contracts and $11.8 billion in remaining deal value that together show a large backlog.
- Valuation measures remain extreme with trailing price/earnings in the triple digits and free‑cash‑flow yields below 1%, leaving the share price exposed if growth or margin gains slow.
- Newly reported international pressures include a legal setback in Switzerland, a French intelligence contract moving to a domestic provider, and renewed UK NHS scrutiny, all of which raise questions about Palantir's non‑U.S. growth path.
- Analysts and investors are split: Wolfe Research resumed coverage with a cautious neutral view on valuation, FactSet‑tracked targets imply substantial upside from current levels, and notable investors such as Michael Burry hold public bearish positions, which together heighten near‑term volatility risks as the company converts backlog into revenue.